Efficacy of Sertraline in Severe Generalized Social Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled Study
J Clin Psychiatry 2003;64(7):785-792
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Generalized social anxiety disorder
is an early onset, highly chronic, frequently disabling disorder
with a lifetime prevalence of approximately 13%. The goal of the
current study was to evaluate the efficacy and tolerability of
sertraline for the treatment of severe generalized social anxiety
disorder in adults.
Method: After a 1-week single-blind placebo
lead-in period, patients with DSM-IV generalized social phobia
were randomly assigned to 12 weeks of double-blind treatment with
flexible doses of sertraline (50-200 mg/day) or placebo. Primary
efficacy outcomes were the mean change in the Liebowitz Social
Anxiety Scale (LSAS) total score and the responder rate for the
Clinical Global Impressions-Improvement scale (CGI-I), defined as
a CGI-I score <= 2. Data were collected in 2000 and 2001.
Results: 211 patients were randomly assigned to
sertraline (intent-to-treat [ITT] sample, 205), and 204 patients,
to placebo (ITT sample, 196). At week 12, sertraline produced a
significantly greater reduction in LSAS total score compared with
placebo (mean last-observation-carried-forward [LOCF] change from
baseline: -31.0 vs. -21.7; p = .001) and a greater proportion of
responders (CGI-I score <= 2: 55.6% vs. 29% among week 12
completers and 46.8% vs. 25.5% in the ITT-LOCF sample; p <
.001 for both comparisons). Sertraline was well tolerated, with
7.6% of patients discontinuing due to adverse events versus 2.9%
of placebo-treated patients.